Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 401–500 of 1,002
Acute pharmacological modulation of mGluR8 reduces measures of anxiety
Duvoisin, R. M., Pfankuch, T., Wilson, J. M., Grabell, J., Chhajlani, V., Brown, D. G., Johnson, E., & Raber, J. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.04.006 · Cited by 78
Degn, M., Lambertsen, K. L., Petersen, G. L., Meldgaard, M., Artmann, A., Clausen, B. H., Hansen, S. H., Finsen, B. R., Hansen, H. S., & Lund, T. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04892.x · Cited by 91
“Recently, potent and selective FAAH inhibitors have been discovered, which allow inhibition of 2-AG and NAE degradation in vivo (Kathuria et al. 2003; Maione et al. 2006).”
BackgroundInteractions between endocannabinoids and stress-induced decreased sensitivity to natural reward
Rademacher, D. J., & Hillard, C. J. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.013 · Cited by 91
“…decreases in sucrose preference The potent FAAH inhibitor, URB597, crosses the blood-brain barrier and produces rapid (i.e., within 30 min) and long-lasting (i.e., at least 6 hrs) effects on brain AEA (Fegley et al., 2005) but not 2-AG content (Kathuria et al., 2003;Patel et al., 2005a).”
BackgroundFatty Acid Amide Hydrolase: From Characterization to Therapeutics
Labar, G., & Michaux, C. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790157 · Cited by 98
de Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega‐Gutiérrez, S., Fernández‐Ruíz, J., & Marzo, V. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.011 · Cited by 89
A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis
Hernández‐Torres, G., Cipriano, M., Hedén, E., Björklund, E., Canales, Á., Zian, D., Feliú, A., Mecha, M., Guaza, C., Fowler, C. J., et al. (2014) · Angewandte Chemie · doi:10.1002/ange.201407807 · Cited by 86
Macamides and their synthetic analogs: Evaluation of in vitro FAAH inhibition
Wu, H., Kelley, C. J., Pino‐Figueroa, A. J., Vu, H., & Maher, T. J. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.06.034 · Cited by 85
Cannabinoids and emotionality: a neuroanatomical perspective
McLaughlin, R. J., & Gobbi, G. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.052 · Cited by 92
Chapter 5 The Endocannabinoid System as A Target for Novel Anxiolytic and Antidepressant Drugs
Gaetani, S., Dipasquale, P., Romano, A., Righetti, L., Cassano, T., Piomelli, D., & Cuomo, V. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)85005-8 · Cited by 83
Self-citationFride, E., Suris, R., Weidenfeld, J., & Mechoulam, R. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00016 · Cited by 87
Microglia produce and hydrolyze palmitoylethanolamide
Muccioli, G. G., & Stella, N. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.05.015 · Cited by 86
“Several reports have shown that FAAH hydrolyzes 2-AG when experiments are performed with homogenates, but pharmacological inhibition and genetic deletion of FAAH does not affect 2-AG levels in intact cells and tissue (Kathuria et al. 2003; Patel et al. 2005).”
BackgroundRepeated cannabinoid administration increases indices of noradrenergic activity in rats
Page, M. E., Oropeza, V. C., Sparks, S. E., Qian, Y., Menko, A. S., & Bockstaele, E. J. V. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.12.020 · Cited by 83
“Other studies have shown that blocking anandamide hydrolysis (by inhibiting fatty acid amide hydrolase) results in anxiolytic effects in two different models of anxiety (Kathuria et al. 2003).”
BackgroundRossi, S., De Chiara, V., Musella, A., Sacchetti, L., Cantarella, C., Castelli, M., Cavasinni, F., Motta, C., Studer, V., Bernardi, G., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064196 · Cited by 82
“The lifespan of the endocannabinoid anandamide (AEA) is regulated by the fatty acid amide hydrolase (FAAH), which cleaves and increases tissue levels of AEA (Kathuria et al., 2003; McKinney and Cravatt, 2005; Maccarrone et al., 2008).”
BackgroundInfluentialEndocannabinoid-Based Therapies
Piomelli, D., & Tagne, A. M. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-021800 · Cited by 86
Self-citationFavia, A. D., Habrant, D., Scarpelli, R., Migliore, M., Albani, C., Bertozzi, S. M., Dionisi, M., Tarozzo, G., Piomelli, D., Cavalli, A., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3011146 · Cited by 86
Self-citationFalenski, K. W., Thorpe, A. J., Schlosburg, J. E., Cravatt, B. F., Abdullah, R. A., Smith, T. H., Selley, D. E., Lichtman, A. H., & Sim-Selley, L. J. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.44 · Cited by 83
“Piomelli and colleagues initially reported the development of URB532 and URB597 (Kathuria et al., 2003), FAAH inhibitors that produced anxiolytic and analgesic effects in the absence of catalepsy, hypothermia or appetite stimulation.”
Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity
Segev, A., Korem, N., Zer‐Aviv, T. M., Abush, H., Lange, R., Sauber, G., Hillard, C. J., & Akirav, I. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0135-4 · Cited by 91
Oleamide: A Fatty Acid Amide Signaling Molecule in the Cardiovascular System?
Hiley, C. R., & Hoi, M. P. M. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00004.x · Cited by 81
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate
Rea, K., Roche, M., & Finn, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707440 · Cited by 78
Endocannabinoid Regulation of Acute and Protracted Nicotine Withdrawal: Effect of FAAH Inhibition
Cippitelli, A., Astarita, G., Duranti, A., Caprioli, G., Ubaldi, M., Stopponi, S., Kallupi, M., Sagratini, G., Rodrìguez de Fonseca, F., Piomelli, D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028142 · Cited by 81
“3 mg/kg) or vehicle was given 120 min prior the signs’ observation and locomotor performance, since FAAH inhibition by URB597 occurs rapidly (,15 minutes) and persists more than six hours [34,36].”
BackgroundMethodInfluentialSelf-citationEndocannabinoids and the Heart
Hiley, C. R. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318192671d · Cited by 90
“URB532 and URB597, which have IC50 values around 1 mM, are carbamates and lack the characteristic long-chain fatty acid moiety of both the endocannabinoids and the other FAAH inhibitors.(66) In addition to hydrolyzing anandamide, FAAH acts upon other fatty acid amides including the primary amide, oleamide, which is ac…”
BackgroundCB1 knockout mice display impaired functionality of 5‐HT1A and 5‐HT2A/C receptors
Mato, S., Aso, E., Castro, E., Martín, M., Valverde, O., Maldonado, R. J., & Pazos, Á. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04961.x · Cited by 80
“Consistently, activation of CB1 receptors induces anxiolytic-like responses (Kathuria et al. 2003; Patel and Hillard 2006; Braida et al. 2007), whereas the CB1 receptor antagonist rimonabant induces anxiety-like effects in the rat (Navarro et al.”
BackgroundPerra, S., Pillolla, G., Melis, M., Muntoni, A. L., Gessa, G. L., & Pistis, M. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0195-0 · Cited by 85
“This compoundwas demonstrated to induce a rapid and prolonged increase in brain anadamide but not 2AG (Kathuria et al. 2003).”
BackgroundInfluentialDrew, G. M., Mitchell, V. A., & Vaughan, C. W. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4876-07.2008 · Cited by 83
“Modulation of the endocannabinoid system represents a promising new target for anxiety and chronic pain states (Kathuria et al., 2003; Costa et al., 2006; Jayamanne et al., 2006; La Rana et al., 2006).”
BackgroundTsuboi, K., Zhao, L.-Y., Okamoto, Y., Araki, N., Ueno, M., Sakamoto, H., & Ueda, N. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.03.005 · Cited by 86
Pacher, P., Bátkai, S., Osei‐Hyiaman, D., Offertáler, L., Liu, J., Harvey-White, J., Brassai, A., Járai, Z., Cravatt, B. F., & Kunos, G. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00107.2005 · Cited by 86
“Phase III hemodynamic effects of AEA are mediated by cannabinoid type 1 (CB1) receptors in both FAAH ϩ/ϩ (A) and FAAH Ϫ/Ϫ (B) mice.”
BackgroundInfluentialWilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
“Likewise, inhibitors of fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996, 2001; Kathuria et al., 2003) and monoacylglycerol lipase (MAGL) (Dinh et al.”
InfluentialBedse, G., Hill, M. N., & Patel, S. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.01.015 · Cited by 83
“Development of efficacious fatty-acid amide hydrolase (FAAH) inhibitors at the turn of the century, which increase central and peripheral AEA signaling (13), propelled this class of compounds into clinical trials for pain and addiction (14, 15), and human experimental studies of anxiety and stress-reactivity (16).”
BackgroundStarowicz, K., Makuch, W., Osikowicz, M., Piscitelli, F., Petrosino, S., Marzo, V. D., & Przewłocka, B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.11.021 · Cited by 86
Suplita, R. L., Gutierrez, T., Fegley, D., Piomelli, D., & Hohmann, A. G. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.10.007 · Cited by 80
“Our data are consistent with the ability of FAAH inhibitors to selectively enhance accumulation of anandamide, but not 2-AG (Cravatt et al., 2001; Lichtman et al., 2002; Kathuria et al., 2003; Fegley et al., 2005).”
BackgroundMethodResultSelf-citationResstel, L. B. M., Lisboa, S. F. D. S., de Aguiar, D. C., Corrêa, F. M. D. A., & Guimarães, F. S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1156-1 · Cited by 82
“The anxiolytic effect of the latter compound is paralleled by an increase in AEA concentrations in the CNS (Bortolato et al. 2006; Kathuria et al. 2003), suggesting the involvement of this endocannabinoid.”
InfluentialRock, E. M., Limebeer, C. L., Mechoulam, R., Piomelli, D., & Parker, L. A. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0970-1 · Cited by 74
“The doses of URB (0.1 and 0.3 mg/kg) were chosen based upon results showing that in vivo FAAH activity is blocked with a half-maximal inhibitory dose (ID50) of 0.15 mg/kg ip with concurrent increase in brain AEA (Kathuria et al. 2003; Fegley et al. 2005).”
BackgroundMethodSelf-citationVilela, L., Medeiros, D. D. C., Rezende, G. H. D. S. E., de Oliveira, A. C. P., Moraes, M. F. D., & Moreira, F. A. (2013) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.11.006 · Cited by 86
Berardi, A., Schelling, G., & Campolongo, P. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.024 · Cited by 82
“Moreover, the FAAH inhibitor AM3506 enhanced auditory fear conditioning extinction when systemically or intra-amygdala administered; the effect was mediated by anandamide activation of cannabinoid receptors [137].”
BackgroundInfluentialCannabinoid interventions for PTSD: Where to next?
Ney, L. J., Matthews, A. J., Bruno, R., & Felmingham, K. L. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.03.017 · Cited by 82
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
Meye, F. J., Trezza, V, Vanderschuren, L. J. M. J., Ramakers, G. M. J., & Adan, R. A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.145 · Cited by 76
Campos, A. C., Ferreira, F. R., Guimarães, F. S., & Lemos, J. I. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.062 · Cited by 83
Clapper, J. R., Vacondio, F., King, A. R., Duranti, A., Tontini, A., Silva, C., Sanchini, S., Tarzia, G., Mor, M., & Piomelli, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900210 · Cited by 88
Self-citationRole of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia
Connell, K., Bolton, N., Olsen, D., Piomelli, D., & Hohmann, A. G. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.12.008 · Cited by 85
Self-citationStructure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase
Hardouin, C., Kelso, M. J., Romero, F. A., Rayl, T. J., Leung, D., Hwang, I., Cravatt, B. F., & Boger, D. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061414r · Cited by 84
Stress disrupts engram ensembles in lateral amygdala to generalize threat memory in mice
Lesuis, S. L., Park, S., Hoorn, A., Rashid, A. J., Mocle, A. J., Salter, E. W., Vislavski, S., Gray, M. T., Torelli, A. M., Cristofaro, A. D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.034 · Cited by 90
“…increase AEA levels in the LA, we disrupted the function of FAAH (fatty acid amide hydrolase 70 ), an enzyme critical for AEA degradation, by using either a CRISPR-based knockdown of FAAH (AAV-SaCas9-sgFAAH 71 ) or microinjecting a drug that inhibits FAAH activity (URB597 72 ) (Figure S4C).”
Thors, L., Bergh, A. R. J., Persson, E., Hammarsten, P., Stattin, P. E., Egevad, L., Granfors, T., & Fowler, C. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012275 · Cited by 80
“FAAH inhibitors, which do not produce the sort of central behavioural effects associated with cannabinoids like D9-tetrahydrocannabinol [13], are currently in drug development, primarily with pain as a therapeutic target, and the leading compound is in phase II of its development.”
BackgroundKaraliota, S., Siafaka‐Kapadai, A., Gontinou, C., Psarra, K., & Mavri‐Vavayanni, M. (2009) · Obesity · doi:10.1038/oby.2009.177 · Cited by 79
“URB597 inhibits FAAH activity in vivo and in vitro and this effect appears to be rather selective (25,43,44) indicating that the reduction of adipocyte differentiation caused by URB597 was due to the specific inhibition of FAAH.”
BackgroundTemporal changes in N‐acylethanolamine content and metabolism throughout the peri‐adolescent period
Lee, T. T. ‐., Hill, M. N., Hillard, C. J., & Gorzalka, B. B. (2013) · Synapse · doi:10.1002/syn.21609 · Cited by 68
“Similarly, inhibition of FAAH has been shown to reduce anxiety in an array of animal models (Hill et al., in press; Kathuria et al., 2003; Kinsey et al., 2011; Rossi et al., 2010), although one caveat of these findings is that the anxiolytic effects of FAAH inhibition are dependent on factors such…”
BackgroundLazáry, J., Lazáry, Á., Gonda, X., Benkő, A., Molnár, E., Hunyady, L., Juhász, G., & Bagdy, G. (2009) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.31024 · Cited by 75
“The recently discovered Endocannabinoid System (ECS) has been implicated in the pathomechanism of anxiety based on pharmacological and genetic studies [Martin et al., 2002; Kathuria et al., 2003; Haller et al., 2004; Bortolato et al., 2006; Moreira et al., 2007].”
BackgroundNiforatos, W., Zhang, X., Lake, M. R., Walter, K. A., Neelands, T. R., Holzman, T. F., Scott, V., Faltynek, C. R., Moreland, R. B., & Chen, J. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033621 · Cited by 75
“because of its lack of activities on FAAH-related enzymes and 47 ion channels/receptors; consequently, it has been extensively used as a pharmacological tool to examine the role of FAAH in pain and anxiety (Kathuria et al., 2003; Gobbi et al., 2005).”
BackgroundMethodInfluentialKarbarz, M. J., Luo, L., Chang, L., Tham, C.-S., Palmer, J. A., Wilson, S. J., Wennerholm, M. L., Brown, S. M., Scott, B. P., Apodaca, R. L., et al. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31818c7cbd · Cited by 74
Dowie, M. J., Howard, M. L., Nicholson, L. F. B., Faull, R. L. M., Hannan, A. J., & Glass, M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.056 · Cited by 78
Romero, F. A., Du, W., Hwang, I., Rayl, T. J., Kimball, F. S., Leung, D., Hoover, H. S., Apodaca, R. L., Breitenbucher, J. G., Cravatt, B. F., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0611509 · Cited by 80
Bukalo, O., Pinard, C. R., & Holmes, A. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12779 · Cited by 67
Ramesh, D., Gamage, T. F., Vanuytsel, T., Owens, R. A., Abdullah, R. A., Niphakis, M. J., Shea‐Donohue, T., Cravatt, B. F., & Lichtman, A. H. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.269 · Cited by 77
“…models of pain (Ahn et al, 2009; Cravatt et al, 2001; Ghosh et al, 2012; Kinsey et al, 2009; Long et al, 2009a; Schlosburg et al, 2010), anxiety (Kathuria et al, 2003; Patel and Hillard, 2006; Kinsey et al, 2011; Sciolino et al, 2011), and drug dependence (Ramesh et al, 2011; Schlosburg et al,…”
BackgroundMorena, M., Leitl, K. D., Vecchiarelli, H. A., Gray, J. M., Campolongo, P., & Hill, M. N. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.020 · Cited by 76
Lee, J., Marzo, V. D., & Brotchie, J. M. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.016 · Cited by 73
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression
Mangieri, R. A., & Piomelli, D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.003 · Cited by 79
“Administration of URB597 decreased isolation-induced ultrasonic vocalizations in rat pups, and increased the time spent in the open arms of the elevated zero and plus mazes [37,47,86,87].”
BackgroundSelf-citationCassano, T., Gaetani, S., Macheda, T., Laconca, L., Romano, A., Morgese, M. G., Cimmino, C. S., Chiarotti, F., Bambico, F. R., Gobbi, G., et al. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2051-0 · Cited by 72
“A support to this hypothesis can be found in previous microinjection studies revealing that low doses of the FAAH inhibitor URB597 produce anxiolytic-like effects in rats when injected in the prefrontal cortex (Rubino et al. 2008), but not in the vHIPP (Roohbakhsh et al. 2009).”
InfluentialSelf-citationEndocannabinoids and Mental Disorders
Rubino, T., Zamberletti, E., & Parolaro, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-20825-1_9 · Cited by 80
Sex‐dependent effects of endocannabinoid modulation of conditioned fear extinction in rats
Morena, M., Nastase, A. S., Santori, A., Cravatt, B. F., Shansky, R. M., & Hill, M. N. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15341 · Cited by 82
“Doses and timing were chosen based on previously published papers (Colangeli et al., 2017; Kathuria et al., 2003; Morena et al., 2018; Ratano, Palmery, Trezza, & Campolongo, 2017; Sticht et al., 2019) and pilot experiments performed in our laboratory.”
MethodActions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model
Barnes, N. S. A., Mitchell, V. A., Kazantzis, N. P., & Vaughan, C. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13337 · Cited by 73
“…URB597, PF3485 and PF04457845) and MAGL (e.g. JZL184 and KML29) have been characterized, which 78 British Journal of Pharmacology (2016) 173 77–87 elevate brain/peripheral levels of anandamide and 2-AG, respectively, when delivered systemically (e.g. Kathuria et al., 2003; Long et al., 2009a).”
BackgroundNeuronal populations mediating the effects of endocannabinoids on stress and emotionality
Häring, M., Guggenhuber, S., & Lutz, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.12.035 · Cited by 79
“Interestingly, in animal models, cannainergic drugs have been shown to possess biphasic efects depending on the dose (Kathuria et al., 2003; Gobbi t al., 2005; Hill and Gorzalka, 2005; Viveros et al., 2005; ambico et al., 2007).”
Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy
Alhouayek, M., Masquelier, J., & Muccioli, G. G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.009 · Cited by 78
Ho, W. ‐. V., & Randall, M. D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707141 · Cited by 76
“Effects of FAAH and MGL inhibitors on relaxation to anandamide The compound URB597 is an irreversible, selective inhibitor of FAAH and displays no activity at MGL (Kathuria et al., 2003).”
BackgroundInfluentialGervasi, M. G., Rapanelli, M., Ribeiro, M. L., Farina, M., Billi, S. C., Franchi, A. M., & Martínez, S. P. (2008) · Reproduction · doi:10.1530/rep-08-0204 · Cited by 79
Developmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T. ‐., Hill, M. N., & Lee, F. S. (2016) · Genes, Brain and Behavior · doi:10.1111/gbb.12253 · Cited by 67
“Preclinical work demonstrates that pharmacological inhibition of FAAH (e.g. URB-597 and PF-3845; Hill et al. 2007; Kathuria et al. 2003) and AEA transport (AM-404; Bortolato et al. 2006) has anxiolytic properties in several tests of anxiety, including: the elevated zero maze, elevated plus maze,…”
Modulation of Fear and Anxiety by the Endogenous Cannabinoid System
Chhatwal, J. P., & Ressler, K. J. (2007) · CNS Spectrums · doi:10.1017/s1092852900020939 · Cited by 80
“…etal (2002)" Chhatwaletal(2005)M Bortolato et al (2006P Bortolato etal (2006)" Bortolato et al (2006)' Bortolato etal|2006>13 Kathuria et al (2003)14 Manipulation/Drug Type CB1 agonist CB1 antagonist CB1 antagonist CB1 gene knockout CB1 gene knockout CB1 gene knockout FAAH &…”
BackgroundSchuelert, N., Johnson, M. P., Oskins, J. L., Jassal, K., Chambers, M. G., & McDougall, J. J. (2011) · Pain · doi:10.1016/j.pain.2010.11.025 · Cited by 70
“URB597 does not bind to CB1 or CB2 receptors [21], affirming that the effect of URB597 arises as a result of increased endocannabinoid accumulation in tissues leading to cannabinoid receptor activation.”
BackgroundOX1 Orexin/Hypocretin Receptor Signaling through Arachidonic Acid and Endocannabinoid Release
Turunen, P. M., Jäntti, M. H., & Kukkonen, J. P. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.078063 · Cited by 74
“amide hydrolase [FAAH] inhibitor) and CCPA (100 M; Nacylethanolamine-hydrolyzing acid amidase/acidic palmitoyl ethanolamidase inhibitor) (Kathuria et al., 2003; Tsuboi et al., 2004; Long et al., 2009).”
BackgroundLodola, A., Mor, M., Rivara, S., Christov, C. Z., Tarzia, G., Piomelli, D., & Mulholland, A. J. (2007) · Chemical Communications · doi:10.1039/b714136j · Cited by 70
Self-citationManduca, A., Morena, M., Campolongo, P., Servadio, M., Palmery, M., Trabace, L., Hill, M. N., Vanderschuren, L. J. M. J., Cuomo, V., & Trezza, V. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.005 · Cited by 78
Self-citationLiu, J., Çınar, R., Xiong, K., Godlewski, G., Jourdan, T., Lin, Y., Ntambi, J. M., & Kunos, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309469110 · Cited by 73
“Inhibition of FAAH results in localized elevations in the tissue levels of AEA, causing a spectrum of effects that do not include the psychotropic effects of global CB1 receptor (CB1R) activation caused by direct-acting agonists (13) and therefore having better therapeutic potential.”
BackgroundCampolongo, P., Morena, M., Scaccianoce, S., Trezza, V., Chiarotti, F., Schelling, G., Cuomo, V., & Roozendaal, B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.26 · Cited by 78
“The general assumption that enhancement of cannabinoid levels via an inhibition of the anandamide-degrading enzyme fatty acid amide hydrolase (FAAH) results in anxiolytic- and antidepressant-like effects in rodents (Gobbi et al, 2005; Kathuria et al, 2003) has recently been revisited.”
BackgroundSelf-citationInput-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus
Chiu, C. Q., & Castillo, P. E. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.026 · Cited by 77
“In our hands, 1 μM URB597 bath application for 30 minutes modestly but significantly enhances AEA-induced depression of inhibitory transmission in the CA1 region (Control 22 ± 4 % depression, n = 4; URB597 39 ± 5 % depression, n = 3, p<0.05).”
MethodInfluentialCocaine- and amphetamine-regulated transcript (CART): A multifaceted neuropeptide
Ahmadian-Moghadam, H., Sadat‐Shirazi, M., & Zarrindast, M. (2018) · Peptides · doi:10.1016/j.peptides.2018.10.008 · Cited by 77
Haj-Dahmane, S., & Shen, R.-Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.153858 · Cited by 69
“A block of brain tissue containing the area of the DR was dissected, and coronal slices (300–400 m) were cut using a Vibratome slicer (Lancer series 1000; Ted Pella, Reading, CA).”
BackgroundMethodButler, R. K., Rea, K., Lang, Y., Gavin, A. M., & Finn, D. P. (2008) · Pain · doi:10.1016/j.pain.2008.10.002 · Cited by 76
“The dose of URB597 and time of administration were chosen on the basis of previous studies demonstrating its efficacy in rats [22,25] and pilot work in our laboratory demonstrating that this dosing regime enhanced FCA without affecting formalinevoked nociceptive behaviour per se.”
MethodChronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD
Fidelman, S., Zer‐Aviv, T. M., Lange, R., Hillard, C. J., & Akirav, I. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.02.004 · Cited by 75
“FAAH inhibition magnifies and prolongs the action of AEA only in brain areas where AEA is synthesized and released (Fegley et al., 2005; Kathuria et al., 2002).”
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Hasbi, A., Madras, B. K., & George, S. R. (2023) · Brain Sciences · doi:10.3390/brainsci13020325 · Cited by 79
Monoglyceride lipase: Structure and inhibitors
Scalvini, L., Piomelli, D., & Mor, M. (2015) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2015.07.011 · Cited by 81
“, 2011), for the modulation of stress responses and anxiety (Kathuria et al., 2003; Bortolato et al., 2007) and contributes to the control of nociceptive transmission (Clapper et al.”
BackgroundSelf-citationHayase, T., Yamamoto, Y., & Yamamoto, K. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00012 · Cited by 75
“Among these anxiolytic drugs, the effects of anandamide (arachidonylethanolamide: AEA), an endogenous cannabinoid (CB) receptor ligand, have been discussed recently (Devane et al., 1992; Chaperon and Thiebot, 1999; Kathuria et al., 2003).”
BackgroundInfluentialEndocannabinoids mediate anxiolytic-like effect of acetaminophen via CB1 receptors
Umathe, S. N., Manna, S. S. S., Utturwar, K. S., & Jain, N. S. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.020 · Cited by 74
“The agents that inhibit anandamide transport, or prevent its degradation by inhibiting FAAH are shown to enhance the CB1 receptor-mediated behavioral effects of anandamide (Giuffrida et al., 2000; Kathuria et al., 2003).”
Facilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice
Gomes, F. V., Casarotto, P. C., Resstel, L. B. M., & Guimarães, F. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.027 · Cited by 74
“Although cannabidiol effects could involve several mechanisms (Izzo et al., 2009), it can enhance endocannabinoid-mediated actions by inhibiting the hydrolysis and reuptake of AEA (Bisogno et al., 2001).”
InfluentialTrezza, V., Campolongo, P., Manduca, A., Morena, M., Palmery, M., Vanderschuren, L. J. M. J., & Cuomo, V. (2012) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2012.00002 · Cited by 76
“, endocannabinoids [mainly anandamide and 2arachidonoylglycerol (2-AG)], are synthesized on demand in an activity-dependent manner and released from postsynaptic neurons (Freund et al., 2003; Piomelli, 2003).”
BackgroundInfluentialSelf-citationGray, J. M., Wilson, C. D., Lee, T. T. Y., Pittman, Q. J., Deussing, J. M., Hillard, C. J., McEwen, B. S., Schulkin, J., Karatsoreos, I. N., Patel, S., et al. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.01.004 · Cited by 67
“, 2015), these data create a framework to further explore the stresslinked mechanisms contributing to states of compromised AEA signaling, and understanding its possible application to anxiety-like disorders (Kathuria et al., 2003).”
BackgroundPotential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Galaj, E., & Xi, Z.-X. (2019) · CNS Drugs · doi:10.1007/s40263-019-00664-w · Cited by 61
Mor, M., Lodola, A., Rivara, S., Vacondio, F., Duranti, A., Tontini, A., Sanchini, S., Piersanti, G., Clapper, J. R., King, A. R., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701631z · Cited by 74
“…at the 3 ′ -position of the biphenyl nucleus yielded FAAH inhibitors with potencies in the low nanomolar concentration range [e.g., 1 (IC 50 = 4.6 nM)], 29 a compound with a remarkable selectivity vs monoglyceride lipase (MGL), 33 triacylglycerol hydrolase (TGH) and triacylglycerol lipase (TGL).”
InfluentialSelf-citationMorena, M., Aukema, R. J., Leitl, K. D., Rashid, A. J., Vecchiarelli, H. A., Josselyn, S. A., & Hill, M. N. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2251-18.2018 · Cited by 76
“Consistently, increased AEA signaling through genetic deletion or pharmacological inhibition of FAAH systemically or directly into the BLA mitigates neuroendocrine and behavioral responses to stress (Kathuria et al., 2003; Bambico et al., 2010; Morena et al., 2016a).”
BackgroundPaulus, M. P., Stein, M. B., Simmons, A. N., Risbrough, V. B., Halter, R. J., & Chaplan, S. R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00936-w · Cited by 71
“Finally, others [15, 17] reported that the FAAH inhibitor PF-3845 decreased mouse marble burying.”
BackgroundBellocchio, L., Inchingolo, A. D., Inchingolo, A. M., Lorusso, F., Malcangi, G., Santacroce, L., Scarano, A., Bordea, I. R., Hazballa, D., D’Oria, M. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158329 · Cited by 82
“These compounds are represented by inhibitors of endocannabinoid re-uptake, such as AM 404 [30], VDM-11, UCM-707 and OMDM-2 [31], and by inhibitors of anandamide hydrolysis, such as URB532, URB597 [32].”
BackgroundChiral 1,3,4-Oxadiazol-2-ones as Highly Selective FAAH Inhibitors
Patel, J. Z., Parkkari, T., Laitinen, T., Kaczor, A. A., Saario, S. M., Savinainen, J. R., Navia‐Paldanius, D., Cipriano, M., Leppänen, J., Koshevoy, I. O., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400923s · Cited by 72
Coulon, D., Faure, L., Grison, M., Wattelet‐Boyer, V., & Bessoule, J. (2011) · Biochimie · doi:10.1016/j.biochi.2011.04.023 · Cited by 77
Wiskerke, J., Irimia, C., Cravatt, B. F., Vries, T. J. D., Schoffelmeer, A. N. M., Pattij, T., & Parsons, L. H. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300036b · Cited by 77
Wilkerson, J. L., Niphakis, M. J., Grim, T. W., Mustafa, M. A., Abdullah, R. A., Poklis, J. L., Dewey, W. L., Akbarali, H. I., Banks, M. L., Wise, L. E., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229971 · Cited by 69
“The actions of these endocannabinoids are short-lived because of rapid degradation by their respective primary hydrolytic enzymes, monoacylglycerol lipase (MAGL) (Dinh et al., 2002; Long et al., 2009) and fatty acid amide hydrolase (Cravatt et al., 1996, 2001; Kathuria et al., 2003).”
BackgroundFatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease
Celorrio, M., Fernández‐Suárez, D., Rojo-Bustamante, E., Echeverry‐Alzate, V., Ramírez, M. J., Hillard, C. J., López‐Moreno, J. A., Maldonado, R. J., Oyarzábal, J., Franco, R., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.06.010 · Cited by 73
Zimmermann, T., Bartsch, J., Beer, A., Lomazzo, E., Guggenhuber, S., Lange, M. D., Bîndilă, L., Pape, H., & Lutz, B. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0274-7 · Cited by 75
“Pharmacological blockade of the enzyme with selective FAAH inhibitors such as URB597, leading to increased AEA levels, exerts anxiolytic [14, 16, 35], antidepressant [17] and analgesic [36] effects.”
BackgroundOddi, S., Dainese, E., Sandiford, S. L., Fezza, F., Lanuti, M., Chiurchiù, V., Totaro, A., Catanzaro, G., Barcaroli, D., Laurenzi, V. D., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01658.x · Cited by 67
“, 2001; Cravatt and Lichtman, 2004), anxiety (Kathuria et al., 2003), spasticity (Smith et al.”
BackgroundHaney, M., & Evins, A. E. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.251 · Cited by 68
Endocannabinoid system and pain: an introduction
Burston, J. J., & Woodhams, S. G. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003650 · Cited by 78
Marco, E. M., & Laviola, G. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111408459 · Cited by 65
“DAGLs are distributed to the developing axons of pyramidal neurons (Mulder et al., 2008), while in the adult brain DAGLa is mainly localized in dendrites (Katona et al., 2006).”
BackgroundLisboa, S. F. D. S., Resstel, L. B. M., de Aguiar, D. C., & Guimarães, F. S. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.07.032 · Cited by 70
Lodola, A., Mor, M., Hermann, J. C., Tarzia, G., Piomelli, D., & Mulholland, A. J. (2005) · Chemical Communications · doi:10.1039/b503887a · Cited by 67
Self-citationFunctionalization of β-Caryophyllene Generates Novel Polypharmacology in the Endocannabinoid System
Chicca, A., Caprioglio, D., Minassi, A., Petrucci, V., Appendino, G., Taglialatela‐Scafati, O., & Gertsch, J. (2014) · ACS Chemical Biology · doi:10.1021/cb500177c · Cited by 67
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.